You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Harmony Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Harmony
International Patents:53
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Harmony

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 RX Yes No ⤷  Try for Free ⤷  Try for Free
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 RX Yes No 8,486,947 ⤷  Try for Free ⤷  Try for Free
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 RX Yes No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Harmony

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-002 Aug 14, 2019 7,910,605 ⤷  Try for Free
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-002 Aug 14, 2019 7,169,928 ⤷  Try for Free
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 7,169,928 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Harmony Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1428820 2016/038 Ireland ⤷  Try for Free PRODUCT NAME: PITOLISANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SUCH AS HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/15/1068 20160331
1428820 CA 2016 00042 Denmark ⤷  Try for Free PRODUCT NAME: PITOLISANT OG FARMACEUTISK ACCEPTABLE SALTE HERAF, SASOM PITOLISANT HYDROCHLORID; REG. NO/DATE: EU/1/15/1068 20160404
1428820 122016000073 Germany ⤷  Try for Free PRODUCT NAME: PITOLISANT UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE, WIE DAS HYDROCHLORID; REGISTRATION NO/DATE: EU/1/15/1068 20160331
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Harmony Biosciences' Market Position, Strengths & Strategic Insights

Last updated: February 16, 2025

In the dynamic world of pharmaceuticals, Harmony Biosciences has emerged as a significant player, particularly in the realm of rare neurological disorders. This article delves into the company's market position, strengths, and strategic insights, providing a comprehensive competitive landscape analysis.

Harmony Biosciences: A Rising Star in Rare Neurological Disorders

Harmony Biosciences has established itself as a leading pharmaceutical company specializing in the development and commercialization of novel therapies for rare neurological disorders. With a laser-focused approach on addressing unmet medical needs, the company has positioned itself at the forefront of innovation in this niche market[2].

Market Position and Share

As of Q3 2024, Harmony Biosciences held a significant market share within the Major Pharmaceutical Preparations Industry:

  • 12 Months Ending Q3 2024: 7.41% market share
  • Most Recent Quarter (Q3 2024): 8.47% market share[1]

These figures demonstrate Harmony's strong and growing presence in the pharmaceutical landscape, particularly in its specialized field.

WAKIX: The Flagship Product

At the heart of Harmony Biosciences' success lies WAKIX (pitolisant), the company's lead product. WAKIX has shown impressive market performance:

  • 2023 Total Revenue: $406.3 million
  • Year-over-Year Growth: 35.2%
  • Market Share in Narcolepsy Treatment: Approximately 40%[7]

These figures underscore the significant impact WAKIX has had on the company's growth and market position.

Strengths: The Pillars of Harmony's Success

1. Focused Specialty Approach

Harmony Biosciences' unwavering focus on rare neurological disorders sets it apart from many competitors. As of Q4 2023, the company maintained a 100% focus on central nervous system treatments[7]. This specialized approach allows Harmony to concentrate its resources and expertise, potentially leading to more innovative and effective therapies.

2. Robust Intellectual Property Portfolio

The company's strong intellectual property strategy is a key strength:

  • Total Patent Portfolio: 15 active patents
  • Patent Protection for WAKIX: Extended until 2037
  • Pending Patent Applications: 7 in various stages of review[7]

This robust IP portfolio provides Harmony with a competitive edge and protects its innovations from potential competitors.

3. Consistent Revenue Growth

Harmony Biosciences has demonstrated impressive financial performance in recent years:

Year Total Revenue Growth Rate
2021 $278.5 million N/A
2022 $362.7 million 30.2%
2023 $506.9 million 39.8% [7]

This consistent growth trajectory showcases the company's ability to capitalize on market opportunities and expand its presence in the pharmaceutical industry.

4. Strong Research and Development Capabilities

Harmony's commitment to R&D is evident in its investments and ongoing clinical trials:

  • R&D Expenditure in 2023: $87.6 million
  • Current Active Clinical Trials: 4 distinct neurological disorder programs
  • Research Team Size: 62 dedicated scientists and researchers[7]

This focus on R&D positions Harmony to continue developing innovative therapies and expanding its product pipeline.

Strategic Insights: Navigating the Competitive Landscape

Expansion into New Indications

One of Harmony's key strategies is the potential expansion of WAKIX into additional neurological disorder indications. This approach could significantly broaden the company's market reach:

  • Obstructive Sleep Apnea (OSA) market potential: Estimated $2.8 billion by 2026
  • Idiopathic Hypersomnia treatment market: Projected value of $450 million by 2025[7]

Leveraging the Growing Rare Disease Market

The global rare disease market presents significant opportunities for Harmony:

  • Global rare disease market size: $262.7 billion in 2023
  • Compound Annual Growth Rate (CAGR): 12.3% from 2023-2030[7]

By focusing on rare neurological disorders, Harmony is well-positioned to capitalize on this growing market segment.

Strategic Partnerships and Acquisitions

Harmony Biosciences could further strengthen its market position through strategic partnerships or acquisitions:

Partnership Type Estimated Value Range Potential Impact
Research Collaboration $50-100 million New therapeutic development
Acquisition Target $500-750 million Expanded product portfolio [7]

Such strategic moves could accelerate Harmony's growth and expand its capabilities in the neuroscience sector.

Competitive Landscape: Key Players and Market Dynamics

Major Competitors

Harmony Biosciences faces competition from established pharmaceutical companies in the neurological disorders space:

Competitor Market Cap Neurological Disorder Drugs
Jazz Pharmaceuticals $7.2 billion Xyrem, Sunosi
Axsome Therapeutics $3.6 billion Auvelity
Avadel Pharmaceuticals $412 million Lumryz [7]

These competitors present challenges in terms of market share and product development, but also highlight the significant market opportunity in this space.

Market Trends and Opportunities

The pharmaceutical industry, particularly in the realm of neurological disorders, is experiencing several key trends:

  1. Increasing demand for effective treatments for sleep and CNS disorders
  2. Growing focus on precision medicine and targeted therapies
  3. Rising interest in combination therapies for complex neurological conditions
  4. Expanding global market for rare disease treatments

Harmony Biosciences is well-positioned to capitalize on these trends, given its specialized focus and strong R&D capabilities.

Future Outlook: Challenges and Opportunities

Potential Challenges

  1. Intense competition in the neurological disorder pharmaceutical market
  2. Complex regulatory environment for pharmaceutical approvals
  3. Potential reimbursement challenges
  4. Risk of generic competition for WAKIX after patent expiration[7]

Growth Opportunities

  1. Expansion into new markets and indications
  2. Development of novel therapies through continued R&D investment
  3. Strategic collaborations to enhance market position and capabilities
  4. Leveraging growing demand for rare disease treatments globally
"Harmony delivered another year of outstanding performance in 2023, with continued strong growth for WAKIX, demonstrating its durability going into year five on the market," - Jeffrey Dayno, President and CEO, Harmony Biosciences[5]

This statement underscores the company's strong market position and potential for continued growth.

Financial Performance and Future Projections

Harmony Biosciences has demonstrated impressive financial performance in recent years:

  • Q4 2024 Net Revenue: $201 million (preliminary)
  • Full Year 2024 Net Revenue: $714 million (preliminary)
  • Year-over-Year Growth: ~23% in Year-Five of WAKIX Launch[9]

Looking ahead, the company has provided guidance for 2025:

  • 2025 WAKIX Net Revenue Guidance: $820 - $860 Million
  • On track for a potential $1 Billion+ opportunity[9]

These projections highlight Harmony's strong growth trajectory and market potential.

Pipeline and Future Catalysts

Harmony Biosciences has a robust pipeline with several key catalysts expected in 2025:

  • Q1: FDA Decision on File Acceptance of Pitolisant sNDA for Idiopathic Hypersomnia
  • Q2: Orexin/BP1.15205 Data Presentation at SLEEP 2025 Conference
  • Q3: Pivotal Phase 3 Topline Data for ZYN002 in Fragile X Syndrome
  • Q4: Initiation of Pitolisant-HD Pivotal Phase 3 Trial in Narcolepsy[9]

This catalyst-rich pipeline demonstrates Harmony's commitment to innovation and expansion in the neurological disorders space.

Key Takeaways

  1. Harmony Biosciences has established a strong market position in rare neurological disorders, with a focus on sleep-wake disorders.
  2. The company's lead product, WAKIX, has shown impressive growth and market penetration.
  3. Harmony's strengths include its focused approach, robust IP portfolio, consistent revenue growth, and strong R&D capabilities.
  4. The company faces competition from established pharmaceutical companies but is well-positioned in the growing rare disease market.
  5. Future growth opportunities include expansion into new indications, strategic partnerships, and leveraging global market trends.
  6. Harmony's strong financial performance and promising pipeline suggest continued growth potential in the coming years.

FAQs

  1. Q: What is Harmony Biosciences' primary focus in the pharmaceutical industry? A: Harmony Biosciences specializes in developing and commercializing novel therapies for rare neurological disorders, with a particular focus on sleep-wake disorders.

  2. Q: How has WAKIX performed in the market? A: WAKIX has shown strong performance, with 2023 total revenue of $406.3 million and a year-over-year growth of 35.2%. It holds approximately 40% market share in narcolepsy treatment.

  3. Q: What are some of Harmony Biosciences' key strengths? A: Key strengths include its focused specialty approach, robust intellectual property portfolio, consistent revenue growth, and strong research and development capabilities.

  4. Q: What potential challenges does Harmony Biosciences face? A: Challenges include intense competition in the neurological disorder market, complex regulatory environments, potential reimbursement issues, and the risk of future generic competition.

  5. Q: What are some future growth opportunities for Harmony Biosciences? A: Growth opportunities include expansion into new indications (such as Obstructive Sleep Apnea and Idiopathic Hypersomnia), strategic partnerships or acquisitions, and leveraging the growing global market for rare disease treatments.

Sources cited: [1] https://csimarket.com/stocks/competitionSEG2.php?code=HRMY [2] https://canvasbusinessmodel.com/blogs/target-market/harmony-biosciences-target-market [5] https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-reports-fourth-quarter-and-full-year-2023 [7] https://dcfmodeling.com/products/hrmy-swot-analysis [9] https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-reports-strong-2024-revenues-provides-2025

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.